Portal Hypertension - Complete Clinical Overview

1. Definition

HVPG = Wedged Hepatic Venous Pressure (WHVP) - Free Hepatic Venous Pressure (FHVP)

• Current Surgical Therapy 14e, p.455; Sleisenger and Fordtran's GI & Liver Disease

2. Pathophysiology

Portal Pressure = Portal Blood Flow × Intrahepatic Resistance

A. Increased Intrahepatic Resistance (Mechanical + Functional)

• Progressive collagen deposition and regenerative nodules distort sinusoidal architecture
• Scarring compresses sinusoids and disrupts normal blood flow

• Contraction of vascular smooth muscle cells, myofibroblasts, and hepatic stellate cells
• Decreased nitric oxide (NO) production by sinusoidal endothelial cells → intrahepatic vasoconstriction
• Increased release of endothelin-1, angiotensinogen, and eicosanoids → further vasoconstriction
• Sinusoidal remodeling with arterio-portal anastomoses in fibrous septa imposes arterial pressures on the low-pressure portal venous system

B. Increased Portal Blood Flow (Hyperdynamic Circulation)

• Splanchnic arterial vasodilation is the key driver - primarily mediated by overproduction of NO in the extrahepatic circulation (a paradox vs. the intrahepatic NO deficiency)
• Other mediators: prostacyclin, TNF-alpha, glucagon
• Splanchnic vasodilation → increased splanchnic venous return → increased portal inflow
• This drives a hyperdynamic circulatory state: increased cardiac output, increased total blood volume, decreased systemic vascular resistance
• Activation of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) → sodium and water retention → further plasma volume expansion

• Intrahepatic: NO deficiency → vasoconstriction → increased resistance
• Extrahepatic (splanchnic): NO excess → vasodilation → increased flow
• Robbins, Cotran & Kumar Pathologic Basis of Disease; Goldman-Cecil Medicine

3. Causes of Portal Hypertension

Prehepatic (Pre-sinusoidal, Extrahepatic)

• Portal vein thrombosis (most common prehepatic cause)
• Splenic vein thrombosis
• Congenital narrowing/stenosis of portal vein
• Splenomegaly with increased splenic blood flow (e.g., myelofibrosis, tropical splenomegaly)
• Arteriovenous fistula (splenic)

Intrahepatic

• Schistosomiasis (most common worldwide cause overall)
• Primary biliary cholangitis (even without cirrhosis)
• Congenital hepatic fibrosis
• Nodular regenerative hyperplasia
• Sarcoidosis / diffuse fibrosing granulomatous disease
• Infiltrative malignancy (primary or metastatic)

• Cirrhosis - by far the leading cause (alcohol, viral hepatitis B/C, NAFLD/NASH, autoimmune)
• Massive fatty change
• Amyloidosis

• Veno-occlusive disease (hepatic sinusoidal obstruction syndrome)
• Focal malignancy with portal vein invasion (especially HCC)

Posthepatic (Post-sinusoidal, Extrahepatic)

• Budd-Chiari syndrome (hepatic vein thrombosis)
• Severe right-sided heart failure
• Constrictive pericarditis
• Inferior vena cava obstruction/web

Key epidemiological point: In North America/Europe, cirrhosis accounts for ~90% of cases. Worldwide, schistosomiasis and portal vein thrombosis are far more common.

• Robbins, Cotran & Kumar Pathologic Basis of Disease; Current Surgical Therapy 14e

4. Clinical Features

Symptoms

• Abdominal distension (ascites)
• Hematemesis or melena (variceal bleeding)
• Altered consciousness, confusion (hepatic encephalopathy)
• Fatigue, malaise
• Symptoms of the underlying liver disease

Signs

• Jaundice, spider angiomas, palmar erythema
• Gynecomastia, testicular atrophy (hyperestrogenism)
• Leukonychia, Dupuytren's contracture
• Hepatomegaly or small liver (late cirrhosis)

1. Variceal hemorrhage - most immediately life-threatening; mortality ranges 5-68% depending on Child-Pugh class
2. Ascites - occurs in 85% of cases from cirrhosis; may lead to SBP or hepatorenal syndrome
3. Hepatic encephalopathy - due to portosystemic shunting (ammonia bypass) and liver insufficiency
4. Spontaneous bacterial peritonitis (SBP) - bacterial translocation from gut into ascitic fluid
5. Hepatorenal syndrome (HRS) - extreme peripheral vasodilation → renal vasoconstriction
6. Hepatopulmonary syndrome / portopulmonary hypertension

• Goldman-Cecil Medicine; Robbins, Cotran & Kumar; Current Surgical Therapy 14e

5. Investigations

Laboratory Tests

Scoring Systems for Severity

• Child-Turcotte-Pugh (CTP) score - based on ascites, encephalopathy, bilirubin, albumin, PT; classifies A (5-6), B (7-9), C (10-15)
• MELD score = [0.957 × LN(creatinine) + 0.378 × LN(bilirubin) + 1.12 × LN(INR) + 0.643] × 10; used for transplant listing
• MELD-Na - incorporates serum sodium for improved mortality prediction

Imaging

• Portal vein diameter > 13 mm (dilated)
• Splenomegaly (>12 cm)
• Ascites
• Reversed/sluggish portal flow on Doppler
• Detection of collaterals (e.g., recanalized umbilical vein)

• Measures portal venous flow velocity and direction
• Hepatofugal flow (reversed) confirms portal hypertension

• Identifies varices, splenomegaly, ascites, caudate lobe hypertrophy
• Detects portal vein thrombosis, Budd-Chiari, HCC
• Demonstrates portosystemic collaterals

• Better delineation of hepatic/portal venous anatomy
• Useful for Budd-Chiari syndrome

Direct Pressure Measurement - Gold Standard

• Transjugular catheterization of hepatic vein
• WHVP - FHVP = HVPG (reflects sinusoidal pressure)
• HVPG ≥ 10 mmHg = clinically significant portal hypertension
• HVPG ≥ 12 mmHg = risk of variceal bleeding and ascites
• HVPG > 20 mmHg = high risk of treatment failure
• Limitation: Only accurate for sinusoidal/postsinusoidal causes (not for prehepatic)

• Newer technique; theoretically accurate for pre-sinusoidal, sinusoidal, and postsinusoidal causes
• PPG = PVP - HVP

Endoscopy

• Mandatory for all patients with suspected portal hypertension
• Diagnoses esophageal varices (grade I-IV), gastric varices (GOV1, GOV2, IGV1, IGV2)
• Portal hypertensive gastropathy - mosaic/snakeskin pattern with cherry-red spots
• Identifies active bleeding source

Liver Biopsy

• Determines etiology and stage of liver disease
• Gold standard for fibrosis staging (Metavir, Ishak scales)
• Not always needed if clinical picture is clear

Serum-Ascites Albumin Gradient (SAAG)

• SAAG ≥ 1.1 g/dL = portal hypertension (97% accuracy)
• SAAG < 1.1 g/dL = exudative cause (malignancy, TB, pancreatitis)
• Frameworks for Internal Medicine; Current Surgical Therapy 14e; Sleisenger and Fordtran's GI & Liver Disease

6. Management

A. Medical Management

• Propranolol (20-80 mg BD) or Nadolol (40-240 mg OD) or Carvedilol (6.25-12.5 mg OD)
• Reduce portal pressure by: β1 blockade (reduces cardiac output) + β2 blockade (splanchnic vasoconstriction)
• Target: reduce HVPG by ≥ 20% from baseline, or to < 12 mmHg
• Used for: primary prophylaxis of first variceal bleed and secondary prophylaxis after banding

• Terlipressin (first-line): splanchnic vasoconstrictor; reduces portal pressure
• Octreotide / Somatostatin: inhibit vasodilatory hormones (glucagon) → splanchnic vasoconstriction
• Start immediately on suspicion of variceal bleed, before endoscopy, continue for 3-5 days

• Short-course prophylactic antibiotics (e.g., ceftriaxone 1g IV OD x 7 days) reduce SBP risk and improve survival

• Spironolactone (aldosterone antagonist, 100-400 mg/day) + Furosemide (40-160 mg/day) - combination preferred
• Target weight loss: 0.5 kg/day (without peripheral oedema), 1 kg/day (with peripheral oedema)
• Refractory ascites: large-volume paracentesis (LVP) + albumin infusion (8 g per litre removed)

• Lactulose reduces gut ammonia absorption
• Rifaximin (non-absorbable antibiotic) reduces secondary prevention of hepatic encephalopathy

B. Endoscopic Management

• Preferred over sclerotherapy for esophageal varices
• Primary prophylaxis: for large varices or varices with red signs in Child B/C patients who cannot tolerate NSBBs
• Acute bleeding: combined with vasoactive drugs (emergency EGD within 12 hours)
• Secondary prophylaxis: EVL every 1-2 weeks until eradication; then surveillance EGD every 3-6 months
• Superior to sclerotherapy: faster eradication, less rebleeding, fewer complications

• Injection of sclerosant (ethanolamine, polidocanol) into varices
• Now second-line to EVL; still used for gastric varices
• Risk of esophageal ulceration, stricture

• Preferred for gastric varices (GOV2, IGV1) where EVL is less effective

• Sengstaken-Blakemore tube, Minnesota tube, Linton-Nachlas tube
• Controls bleeding in ~80% but temporary (max 24 hours); high complication rate (aspiration, esophageal perforation, necrosis)
• Only used as bridge when definitive treatment unavailable

C. Radiological Interventions

• Creates a shunt between hepatic vein and portal vein through hepatic parenchyma using expandable metallic stent
• Reduces portal pressure by bypassing hepatic resistance
• Indications: refractory variceal bleeding, refractory ascites, Budd-Chiari syndrome, hepatorenal syndrome, bridge to transplant
• Contraindications: hepatic encephalopathy (relative), severe right heart failure, polycystic liver disease
• Complication: hepatic encephalopathy (30-50%)
• Has largely replaced surgical shunts in current practice

D. Surgical Management

• Both non-selective and selective shunts achieve >90% hemorrhage control with similar rebleeding rates and survival; encephalopathy is significantly lower with distal splenorenal shunt.

• Sugiura procedure: ligation of gastroesophageal collaterals + esophageal transection + splenectomy
• Now rarely performed; high morbidity/mortality (up to 35%)

• Gold standard and only cure for portal hypertension due to cirrhosis
• Treats both the underlying liver disease and all complications of portal hypertension
• MELD score guides prioritization
• Indicated when MELD ≥ 15, recurrent variceal bleeding despite optimal therapy, refractory ascites, hepatorenal syndrome, or SBP
• Not appropriate for non-cirrhotic etiologies with intact liver function

E. Management of Specific Complications

• Current Surgical Therapy 14e; Goldman-Cecil Medicine; Sleisenger and Fordtran's GI & Liver Disease; Robbins, Cotran & Kumar Pathologic Basis of Disease; Maingot's Abdominal Operations

Recent Evidence (2024-2026)

• A 2025 meta-analysis on non-cirrhotic portal hypertension (PMID 40081810) examined hepatic encephalopathy prevalence, finding it relevant even in non-cirrhotic cases.
• A 2024 systematic review on ectopic variceal bleeding (PMID 38935315) confirmed TIPS as effective management for ectopic varices.
• A 2025 systematic review on portal cavernoma cholangiopathy (PMID 41085547) updated understanding of biliary complications in extrahepatic portal hypertension.